Skip Navigation

Instructions to Authors

Scope of the Journal
HEART Network
Article categories
Submission of manuscripts
Review of manuscripts
Preparation of manuscripts
Reference format
Supplementary data
Sources of funding
Conflict of interest
ARRIVE guidelines
Author contribution form
Open access option for authors
Self-archiving and post-print policy
Copyright information
Permissions information
Online access and offprints
Language editing

Scope of the Journal

The European Journal of Heart Failure is the International Journal of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The Journal publishes reviews and editorials in order to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome.

HEART Network

The European Journal of Heart Failure participates in the HEART network which is a network of Editors from most cardiovascular journals. Information is exchanged between editors on a regular basis. The network has recently approved a common ethics standard.

Its purpose is to ensure transparency and honesty in the scientific process that promotes ethical conduct in performance and publication of research.

The following will be considered as parts of this process:

a. Disclosure of potential conflicts of interest for all involved in the performance of research and in the evaluation and publication process of a manuscript. Relevant relationships with commercial interests should be disclosed according to the guidelines of the journal's sponsoring society, or, when no such guidelines exist, according to those of the AHA, ACC, or ESC.

b. establish thorough review processes particularly alert to discovering scientific fraud and data falsification, redundant or duplicate publication, and plagiarism, and to adopt a uniform standard of dealing with authors guilty of fraudulent practices.

c. to maintain confidentiality and embargos where appropriate.

d. to create uniform criteria to establish authorship. To qualify for authorship, individuals must have made substantial contributions to the intellectual content of the paper in at least one of the following areas: conceived and designed the research, acquired the data, analyzed and interpreted the data, performed statistical analysis, handled funding and supervision, drafted the manuscript, or made critical revision of the manuscript for important intellectual content. Authors must give final approval of the version to be submitted and any revised version to be published. For multi-centre trials, individuals who accept direct responsibility for the manuscript should fully meet the criteria for authorship defined above and contributors not meeting these criteria should be acknowledged.

e. avoidance of false claims of ownership, priority, by attention to previous publications.

f. avoidance of excessive claims of benefits of a product/technique, in the publication as well as with news media.

g. noting compliance with institutional review board requirements and, when appropriate, approved laboratory procedures for animal research, and that the research conforms to the ethical standards of the Declaration of Helsinki, the Geneva Declaration, the Belmont Report, and Good Clinical Practices from the FDA, and the submission conforms to the International Committee of Medical Journal Editors (ICMJE): Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication (Haematologica 89:264, 2005).

Article categories

The European Journal of Heart Failure accepts the following categories of articles:

Full Length Articles These should not exceed 3500 words (excluding references, tables and figures) and may include up to a maximum of 6 figures and/or tables and up to 30 references. Full length articles should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, (7) Acknowledgements, (8) Funding, (9) Conflict of Interest, (10) References, (11) Figure legends, (12) Appendices, (13) Tables, (14) Figures. The Abstract should be divided into the following sections 'Aims', 'Methods and results' and 'Conclusion', it should not exceed 250 words.

Reviews The European Journal of Heart Failure publishes a limited number of scholarly, comprehensive review papers. Reviews should not exceed 3500 words. They should summarize and critically evaluate research in the subject area, and should discuss implications for the future. Reviews have unstructured abstracts with no headings, which should not exceed 250 words and may include up to 45-50 references. Please see below for systematic reviews.

Systematic Reviews: These reviews should follow the format of full length articles, please see above for the required format. These should be submitted as a full length article during the submission process.

Editorials All editorials should be limited to 1500 words (excluding references), with a maximum of 15 references. They do not require an abstract.

Short Reports These reports should not exceed 1500 words and should comprise a background section (~100 words), aims (~50 words), methods (~300 words), results (300 words) and conclusion (250 words). The editorial team reserves the right to decide which of the tables/figures submitted are necessary. A structured abstract not exceeding 250 words is also required for Internet purposes.

Letters to the Editor Relevant correspondence will be considered. This should not exceed 400 words in length excluding references.

Case Reports These reports should not exceed 1200 words. Case Reports should include an unstructured Abstract with no subheadings (not exceeding 100 words), and Introduction, a description of the case(s) under the heading “Case Report” and a discussion of the findings in the context of current practice.

Study Design Papers These should not exceed 3500 words (excluding references, tables, and figures) and may include up to a maximum of 6 figures and/or tables and up to 30 references. Study design papers should be divided into the following sections: (1) Title page, (2) Abstract and up to six Keywords, (3) Introduction, (4) Study Design, (5) Discussion, (6) Acknowledgements, (7) Funding, (8) Conflict of Interest, (9) References, (10) Figure legends, (11) Appendices, (12) Tables, (13) Figures. The Abstract should be divided into the following sections 'Aims', 'Methods', and 'Conclusion', it should not exceed 250 words.

Submission of manuscripts

The European Journal of Heart Failure uses a web-based submission and review system at Online submission facilitates the submission of manuscripts from authors and streamlines the reviewing and publication process.

Authors may send queries concerning the submission process to For enquiries about the review process and journal procedures, the editorial office can be contacted at +44 1482 461778. As a matter of policy, the status of documents will not be discussed by telephone.

Once you have prepared your manuscript according to the instructions below, please go to the online submission system by clicking here. First-time users must click "Register" on the navigation menu at the top of the screen. The system will send an automatic e-mail with your user name and password. Detailed guidelines for authors and reviewers are available at the submission site.

Covering letter The covering letter should include the following:

i) a declaration that "the manuscript, or part of it, has neither been published (except in the form of abstract or thesis) nor is currently under consideration for publication by any other journal";
ii) an explanation as to why your paper would be of particular interest to the readers of the European Journal of Heart Failure;
iii) a statement declaring that all named authors have seen and approved the final version of the manuscript.

Short title: Published papers include a running header (max. 80 characters), which is a shortened version of the article title. Please insert a suggested short title in the ‘Short title’ field on the submission screen.

Review of manuscripts

All manuscripts correctly submitted to the European Journal of Heart Failure will first be reviewed by the Editors. Some manuscripts will be returned to authors at this stage if the paper is deemed inappropriate for publication in the European Journal of Heart Failure, if the paper does not meet submission requirements, or if the paper is not deemed to have a sufficiently high priority. All papers considered suitable by the Editors to progress further in the review process will undergo appropriate peer review and all papers provisionally accepted for publication may undergo a detailed statistical review.

Manuscripts will usually be evaluated by at least two reviewers from an international panel. Editors will make every effort to reach a decision within 6 to 8 weeks of receipt of the manuscript but on some occasions, due to reasons beyond our control, this may take longer.

Authors may supply the names and addresses of three referees to whom the manuscript might be sent for review.

Preparation of manuscripts

Style and spelling: Oxford English spelling should be used. Authors whose first language is not English are requested to have their manuscripts checked carefully before submission. This will help expedite the review process and avoid confusion.

General format: Prepare your manuscript text using a Word processing package (save in .doc or .rtf format). Submissions of text in the form of PDF files are not permitted. Manuscripts should be double-spaced, including text, tables, legends and references.

Number each page. Please avoid footnotes; use instead, and as sparingly as possible, notes within brackets. Enter text in the style and order of the journal. Type references in the correct order and style of the journal. Type unjustified, without hyphenation, except for compound words (where two words are joined to form a new word e.g. end-systolic, non-infarcted). Type headings in the style of the journal. Use the TAB key once for paragraph indents. Where possible use Times New Roman for the text font and Symbol for Greek and special characters. Use the word processing formatting features to indicate Bold, Italic, Greek, Maths, Superscript and Subscript characters. Clearly identify unusual symbols and Greek letters. Differentiate between the letter O and zero, and the letters I and l and the number 1.

Check the final copy of your paper carefully, as any spelling mistakes and errors may be translated into the typeset version.

Abbreviations of standard SI units of measurement only should be used.

Declaration of Helsinki: The authors should state that their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their guardians).

DNA Sequences and GenBank Accession Number: For each and every gene accession number cited in an article, authors should type the accession number in bold, underlined text. Letters in the accession number should always be capitalised. Example: (GenBank accession nos. AI631510, AI631511, AI632198 and BF223228 ), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession no. AA361117).

Title Page: The title page should include the following: (1) the title, (2) the name(s) of authors, (3) the institution(s) where work was performed, (4) the position, institution, and location of all authors, (5) the telephone number, fax number and e-mail address of the corresponding author (6) the institutional affiliations of the authors (including corporate appointments) should be acknowledged in a footnote.

Abstract: All abstracts may not contain more than 250 words and should also be submitted as a separate file. The abstract should be formatted with the following heading: (1) Aims, (2) Methods and Results, (3) Conclusion.

Keywords: A maximum of six keywords may be submitted.

Introduction: This section should provide a rationale for conducting the study within the context of previous work by other authors.

Methods: This section should be sufficiently detailed to enable repetition of the study by other investigators. If pertinent, the section may be divided into headed subsections. For animal studies, this section should contain a statement that "The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985)". Human studies should contain a statement that "The investigation conforms with the principles outlined in the Declaration of Helsinki" (Br Med J 1964;ii:177).In addition details of the ethics committee approval procedures and a statement that all subjects gave written informed consent to participate in the study should be included.

Results: If pertinent, the section may be divided into headed subsections. For presentation of data, figures are preferred to tables. Data should not be duplicated in both figures and tables. Extensive numerical data should be presented in legends to the figures rather than in the main body of text. SI units should be used throughout.

Discussion: Four manuscript pages should in general be enough to compare and interpret the findings of the study with regard to previous work by (other) authors. This section should also contain 1-4 paragraphs dealing with topics that are beyond the scope of the study. Limitations to the study should also be discussed.

Figures: The review process will not begin until all figures are received. Figures should be limited to the number necessary for clarity and must not duplicate data given in tables or in the text. They must be suitable for high quality reproduction and should be submitted in the desired final printed size so that reduction can be avoided. Figures should be no larger than 125 (height) x 180 (width) mm (5 x 7 inches) and should be submitted in a separate file from that of the manuscript.

Colour figures: For colour reproduction in print, you will receive information regarding the costs from Oxford Journals after receipt of your accepted article. Each colour page in print costs approx. £350/EUR520.

Electronic submission of figures: Figures should be saved in TIFF format at a resolution of at least 300 pixels per inch at the final printed size for colour figures and photographs, and 1200 pixels per inch for black and white line drawings. Although some other formats can be translated into TIFF format by the publisher, the conversion may alter the tones, resolution and contrast of the image. Digital colour art should be submitted in CMYK rather than RGB format, as the printing process requires colours to be separated into CMYK and this conversion can alter the intensity and brightness of colours. Therefore authors should be satisfied with the colours in CMYK (both on screen and when printed) before submission. Please also keep in mind that colours can appear differently on different screens and printers. Failure to follow these guides could result in complications and delays.

Photographs: Photographs should be of sufficiently high quality with respect to detail, contrast and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Please indicate the magnification by a rule on the photograph

Line drawings: Please provide these as clear, sharp illustrations, suitable for reproduction as submitted. All labelling should be on the original. Faint and grey shading or stippling will be lost upon reproduction and should be avoided. Where various shadings are used within one figure please ensure that it is easy to differentiate between them, using standard shadings (see the hard copy of the journal for examples). There should be sufficient white space between lines and dots to ensure the areas will not fill in and look grey. If stippling is used, this should be made up of clear black dots with visible white space between them.

Ensure that the size of the lettering is in proportion with the overall dimensions of the drawing. Ideally, the drawings should be submitted in the desired final printed size to avoid reduction. If submitting line drawings which require reduction, please check that the lettering will be clearly legible after the drawing has been reduced to the size at which it will be printed. After reduction, letters should not be smaller than 2 mm in height.

Figure legends: These should be on a separate, numbered page, and grouped under the heading "Legends". Define all symbols and abbreviations used in the figure. Common abbreviations and others in the preceding text should not be redefined in the legend.

Tables: should be typed with double spacing, but minimising redundant space, and each should be placed on a separate sheet. Tables should be submitted, wherever possible, in a portrait, as opposed to landscape, layout. Each Table should be numbered in sequence using Arabic numerals. Tables should also have a title above and an explanatory footnote below. All abbreviations used should be defined in the footnote. NB tables must be submitted in an editable format, such as Excel or Word, and not embedded as an image or presented as an image file.

Acknowledgements: Substantive contributions of individuals, should be noted in the Acknowledgements, positioned before the conflict of interest statement.

Conflict of interest: All authors must make a formal statement indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product. The statement should be positioned before the list of references. If there are no conflicts of interest, please insert the wording 'Conflict of Interest: none declared'.

Reference format

References should be identified in the text by Arabic numerals and numbered in the order cited. All references should be compiled at the end of the article in the Vancouver style, except that ALL authors should be listed.

Complete information should be given for each Reference including the title of the article, abbreviated journal title and page numbers.

Personal communications, manuscripts in preparation and other unpublished data should not be cited in the reference list but may be mentioned in parentheses in the text. Authors should get permission from the source to cite unpublished data. Titles of journals should be abbreviated in accordance with Index Medicus (see list printed annually in the January issue of Index Medicus). If a journal is not listed in Index Medicus then its name should be written out in full.

Article citation example:

1. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006; 8:532-538

If an article has been published online but has not yet been given issue or page numbers please use the Digital Object Identifier (doi) number when referencing the article as in the example below.

2. Asger A, Møller JM, Daugaard PC, Kjær SU, Erik S. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail;doi:10.1016/j.eheart.2008.09.016. Published online ahead of print 12 March 2008.

Chapter citation example:

3. Nichols WW, O'Rourke MF. Aging, high blood pressure and disease in humans. In: Arnold E, ed. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London/Melbourne/Auckland: Lea and Febiger; 1990. p. 398-420.

Webpage citation example:

4. Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14. (28 May 2004)

Where the date in parenthesis refers to the access date.

Supplementary data

Supporting material that is not essential for inclusion in the full text of the manuscript, but would nevertheless benefit the reader, can be made available by the publisher as online-only content, linked to the online manuscript. The material should not be essential to understanding the conclusions of the paper, but should contain data that is additional or complementary and directly relevant to the article content. Such information might include more detailed methods, extended data sets/data analysis, list of Investigators, or additional figures.

All text and figures must be provided in suitable electronic formats (instructions for the preparation of Supplementary data can be viewed here). All material to be considered as Supplementary data must be submitted at the same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted for publication. Please indicate clearly the material intended as Supplementary data upon submission. Also ensure that the Supplementary data is referred to in the main manuscript where necessary.


All manuscripts selected for publication will be reviewed for the appropriateness and accuracy of the statistical methods used and the interpretation of statistical results. All papers submitted should provide in their Methods section a subsection detailing the statistical methods, including the specific method used to summarize the data, the methods used to test their hypothesis testing and (if any) the level of significance used for hypothesis testing.

Sources of funding

Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.

The following rules should be followed:

  • The sentence should begin: ‘This work was supported by …’
  • The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 'NCI at NIH’ (full RIN-approved list of UK funding agencies)
  • Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX CDXXXXXX]’
  • Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX GHXXXXXX]’
  • Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
  • Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.

An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789].

Conflict of interest

When first submitting, all authors must make a formal statement at the time of submission indicating any potential conflict of interest that might constitute an embarrassment to any of the authors if it were not to be declared and were to emerge after publication. Such conflicts might include, but are not limited to, shareholding in or receipt of a grant or consultancy fee from a company whose product features in the submitted manuscript or which manufactures a competing product.
European Journal of Heart Failure follows the guidelines of the International Committee of Medical Journal Editors. A conflict of interest statement must be included in the manuscript after any "Acknowledgements" and "Funding" sections. If there is no conflict of interest, authors must include 'Conflict of Interest: none declared'. Submissions that do not include this section will not be sent for peer review.

ARRIVE guidelines

The contribution of animal research in enabling better health for man and animals is incontrovertible and EJHF is committed to the publication of research studies which use animal models, but demands the same rigorous attention to detail as in clinical trials. Failure to describe research methods and to report results appropriately has scientific and ethical implications for the entire research process and the reputation of those involved in it.

Experiments involving animals should be appropriately designed, correctly analysed and then transparently reported, to both increase the validity of the results, and maximise the scientific gain. A minimum amount of relevant information must be included in manuscripts published in this journal to ensure that the methods and results of a study can be reviewed, analysed and repeated. EJHF will therefore refer to the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines as the basis for the process of reviewing manuscripts of research involving animals.

These guidelines were generated by The National Centre for the Replacement, Refinement and Reduction of Animals in Research, which is an independent scientific organisation, established by the UK Government, in consultation with scientists, statisticians, journal editors and research funders.

Author contribution form

All authors and contributors should submit an author contribution form/statement (download here) specifying their particular role in the study/article. The European Journal of Heart Failure will ask for signed copies of these forms at a date after submission. Articles will not be published until signed contribution forms from all authors have been received. Completed forms should be sent by email or faxed (+44 1482 461779) to the editorial office.

Open access option for authors

European Journal of Heart Failure authors have the option to publish their paper under the Oxford Open initiative; whereby, for a charge, their paper will be made freely available online immediately upon publication. After your manuscript is accepted the corresponding author will be required to accept a mandatory licence to publish agreement. As part of the licensing process you will be asked to indicate whether or not you wish to pay for open access. If you do not select the open access option, your paper will be published with standard subscription-based access and you will not be charged.

You can pay Open Access charges using our Author Services site. This will enable you to pay online with a credit/debit card, or request an invoice by email or post. Open access charges are £1700/$3000/€2550; discounted rates are available for authors based in some developing countries (click here for a list of qualifying countries). Please note that these charges are in addition to any colour charges that may apply.

Orders from the UK will be subject to the current UK VAT charge. For orders from the rest of the European Union, OUP will assume that the service is provided for business purposes. Please provide a VAT number for yourself or your institution and ensure you account for your own local VAT correctly.

Self-archiving and post-print policy

Authors may deposit the post-print of their article into PubMedCentral, other subject repositories or institutional repositories, but must stipulate that public availability be delayed until 12 months after the first online publication. For further details of this policy please visit: Author Self-archiving Policy

Copyright information

It is a condition of publication in the Journal that authors grant an exclusive licence to The European Society of Cardiology. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. As part of the licence agreement, authors may use their own material in other publications provided that the Journal is acknowledged as the original place of publication and Oxford University Press is notified in writing and in advance.

Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.

Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles.

Permissions information

If illustrations or figures are to be duplicated from previously published work, written permission must be obtained both from the publisher and the author, and a credit line giving the source added to the relevant Figure Legend. If text material (250 to 300 words) is to be reproduced from published sources, written permission is required from both publisher and author. For shorter quotations, it is sufficient to add a bibliographic credit. The Letters containing the permission for the reproduction of either text or illustrations must accompany the manuscript. If you have been unable to obtain permission, please indicate this.

If no permissions are required, submit a Word document with your figure stating this, please.


Page proofs will be sent to the corresponding author. Please provide an e-mail address to enable page proofs to be sent as PDF files via e-mail. These should be checked thoroughly for any possible changes or typographic errors. Significant alterations instigated at this stage by the author will be charged to the author.

It is the intention of the Editor to review, correct and publish your article as quickly possible. To achieve this it is important that all of your corrections are returned to us in one all-inclusive mail or fax. Subsequent additional corrections will not be possible, so please ensure that your first communication is complete.

Online access and offprints

Details of free online access will be sent to the corresponding author, who may then circulate them to co-authors. If the purchase of offprints is required, these can be ordered using the Oxford Journals Author Services site when your paper enters production. Late orders submitted after the journal is in press are subject to increased prices.

Orders from the UK will be subject to the current UK VAT charge. For orders from elsewhere in the EU you or your institution should account for VAT by way of a reverse charge. Please provide us with your or your institution’s VAT number.

Language editing

Particularly if English is not your first language, before submitting your manuscript you may wish to have it edited for language. This is not a mandatory step, but may help to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. If you would like information about such services please click here. There are other specialist language editing companies that offer similar services and you can also use any of these. Authors are liable for all costs associated with such services.

Please note that the European Journal of Heart Failure is now published by Wiley-Blackwell.

Please access the journal at:

Please contact Wiley Customer Services for subscription queries.



Prof. Dr. Dirk J. van Veldhuisen